Five Prime Therapeutics Inc. (NASDAQ:FPRX) Director William R. Ringo sold 500 shares of the business’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $52.00, for a total value of $26,000.00. Following the transaction, the director now owns 500 shares in the company, valued at $26,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) opened at 53.93 on Thursday. Five Prime Therapeutics Inc. has a 1-year low of $15.13 and a 1-year high of $55.00. The stock has a 50 day moving average price of $48.99 and a 200 day moving average price of $45.36. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of 6.07 and a beta of 4.46.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.49) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.07. Five Prime Therapeutics had a net margin of 63.88% and a return on equity of 69.59%. The company earned $9.23 million during the quarter, compared to the consensus estimate of $6.38 million. During the same period in the prior year, the business posted ($0.45) EPS. The company’s quarterly revenue was up 46.1% on a year-over-year basis. Analysts forecast that Five Prime Therapeutics Inc. will post ($2.37) earnings per share for the current year.
Several institutional investors have recently bought and sold shares of FPRX. BlackRock Fund Advisors increased its stake in shares of Five Prime Therapeutics by 1.7% in the first quarter. BlackRock Fund Advisors now owns 944,434 shares of the company’s stock valued at $38,372,000 after buying an additional 15,566 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in shares of Five Prime Therapeutics by 11.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,600,000 shares of the company’s stock valued at $105,638,000 after buying an additional 275,000 shares during the period. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Five Prime Therapeutics during the first quarter valued at about $411,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Five Prime Therapeutics by 6.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 79,245 shares of the company’s stock valued at $3,277,000 after buying an additional 4,531 shares during the period. Finally, First Trust Advisors LP purchased a new stake in shares of Five Prime Therapeutics during the second quarter valued at about $1,706,000. Institutional investors own 86.49% of the company’s stock.
Several equities analysts recently issued reports on the company. Leerink Swann restated an “outperform” rating and set a $58.00 price target (up from $45.00) on shares of Five Prime Therapeutics in a research note on Monday, August 8th. Jefferies Group set a $60.00 price target on Five Prime Therapeutics and gave the company a “buy” rating in a research note on Friday, August 5th. Finally, Credit Suisse Group AG restated a “buy” rating on shares of Five Prime Therapeutics in a research note on Tuesday, July 12th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $52.33.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.